Perspective Therapeutics Ownership 2024 | Who Owns Perspective Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

19.62%

Insider Ownership

20.43%

Retail Ownership

59.95%

Institutional Holders

40.00

Perspective Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.07%184,000--Sep 29, 2023

Perspective Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 184.00K shares, compromising 0.07% of its total assets.

Perspective Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 23401900.00%
31 Dec, 222-

As of 31 Mar 23, 40 institutions are holding Perspective Therapeutics's shares, representing an increase of 1900.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2327,854,5194790.38%
31 Dec, 22569,578-

Perspective Therapeutics (CATX) has 27.85M shares outstanding as of 31 Mar 23, up 4790.38% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2319.62%4790.83%
31 Dec, 220.40%-

As of 31 Mar 23, Perspective Therapeutics is held by 19.62% institutional shareholders, representing a 4790.83% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 23321500.00%
31 Dec, 222-

32 institutional shareholders have increased their position in CATX stock as of 31 Mar 23 compared to 2 in the previous quarter (a 1500.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 23--
31 Dec, 22--

- institutional shareholders have reduced their position in CATX stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 23401900.00%27,854,5194790.38%19.62%4790.83%321500.00%--
31 Dec, 222-569,578-0.40%-2---

Perspective Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 18, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy1,800$9.81$17.67K35,971
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy83$10.80$896.40159,985
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy4,504$10.90$49.09K159,902
Jun 13, 2024Spoor Johan M.director, officer CEOP-PurchaseBuy100,000$1.17$117.43K137,572
Jun 04, 2024Woods Lori Adirector-P-PurchaseBuy34,246$1.46$49.99K1,553,984
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy12,000$1.40$16.80K341,716
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy13,006$1.40$18.21K329,716
Jun 03, 2024Williamson Robert F IIIdirector-P-PurchaseBuy55,000$1.38$75.90K423,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy18,656$1.34$25.00K368,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy11,375$1.32$15.02K350,136

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 18, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy1,800$9.81$17.67K35,971
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy83$10.80$896.40159,985
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy4,504$10.90$49.09K159,902
Jun 13, 2024Spoor Johan M.director, officer CEOP-PurchaseBuy100,000$1.17$117.43K137,572
Jun 04, 2024Woods Lori Adirector-P-PurchaseBuy34,246$1.46$49.99K1,553,984
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy12,000$1.40$16.80K341,716
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy13,006$1.40$18.21K329,716
Jun 03, 2024Williamson Robert F IIIdirector-P-PurchaseBuy55,000$1.38$75.90K423,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy18,656$1.34$25.00K368,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy11,375$1.32$15.02K350,136

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 24, 2024Austin Mark Johnofficer VP Finance/Prin Fin&Acct OfficM-ExemptSell30,000$0.36$10.80K120,000

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jul 19, 2024Austin Mark Johnofficer VP Finance/Prin Fin&Acct OfficA-AwardBuy34,500$11.96$412.62K34,500
Jun 24, 2024Williamson Robert F IIIdirector-A-AwardBuy23,000$10.65$244.95K23,000
Jun 24, 2024Morich Frankdirector-A-AwardBuy23,000$10.65$244.95K23,000
Jun 24, 2024Woods Lori Adirector-A-AwardBuy23,000$10.65$244.95K23,000
Jun 24, 2024HENSON HEIDIdirector-A-AwardBuy23,000$10.65$244.95K23,000
Jun 24, 2024Spoor Johan M.director, officer CEOA-AwardBuy500,000$10.65$5.33M500,000
Jun 24, 2024Puhlmann Markusofficer Chief Medical OfficerA-AwardBuy150,000$10.65$1.60M150,000
Jun 24, 2024Hunt Jonathan Robertofficer Chief Financial OfficerA-AwardBuy100,000$10.65$1.06M100,000
Jun 18, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy1,800$9.81$17.67K35,971
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy83$10.80$896.40159,985
Jun 18, 2024Woods Lori Adirector-P-PurchaseBuy4,504$10.90$49.09K159,902
Jun 13, 2024Spoor Johan M.director, officer CEOP-PurchaseBuy100,000$1.17$117.43K137,572
Jun 05, 2024Woods Lori A-Buy----
Jun 04, 2024Woods Lori Adirector-P-PurchaseBuy34,246$1.46$49.99K1,553,984
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy12,000$1.40$16.80K341,716
Jun 03, 2024Hunt Jonathan Robertofficer Chief Financial OfficerP-PurchaseBuy13,006$1.40$18.21K329,716
Jun 03, 2024Williamson Robert F IIIdirector-P-PurchaseBuy55,000$1.38$75.90K423,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy18,656$1.34$25.00K368,792
May 30, 2024Williamson Robert F IIIdirector-P-PurchaseBuy11,375$1.32$15.02K350,136
Apr 24, 2024Austin Mark Johnofficer VP Finance/Prin Fin&Acct OfficM-ExemptSell30,000$0.36$10.80K120,000

The last insider sell of Perspective Therapeutics's stock was made by Austin Mark John on Apr 24 2024, selling 30,000 shares at $0.36 per share (valued at $10.80K). The last insider buy of CATX was made by Hunt Jonathan Robert on Jun 18 2024, buying 1,800 shares at $9.81 per share (worth $17.67K).

Perspective Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20241--
Q2 20241811800.00%
Q1 20241611600.00%

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Perspective Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024---
Q2 202410--
Q1 202416--

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Perspective Therapeutics's stocks.

Perspective Therapeutics Peer Ownership


TickerCompany
FNAParagon 28, Inc.
OFIXOrthofix Medical Inc.
SGHTSight Sciences, Inc.
LUNGPulmonx Corporation
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
LIVNLivaNova PLC
KIDSOrthoPediatrics Corp.
PAVMPAVmed Inc.
SIBNSI-BONE, Inc.
OSAProSomnus, Inc. Common Stock
HYPRHyperfine, Inc.
CVRXCVRx, Inc.

CATX Ownership FAQ


Perspective Therapeutics is owned by institutional shareholders (19.62%), insiders (20.43%), and public (59.95%). The largest institutional shareholder of Perspective Therapeutics is (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.07% of total shares).

As of Mar 2023, there are 40 institutional shareholders of Perspective Therapeutics.